GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. boosted its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 42.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 134,660 shares of the company’s stock after acquiring an additional 40,000 shares during the period. Prescott Group Capital Management L.L.C.’s holdings in GoodRx were worth $626,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Rubric Capital Management LP raised its holdings in shares of GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after acquiring an additional 943,226 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in GoodRx in the 3rd quarter valued at about $11,295,000. Geode Capital Management LLC lifted its holdings in GoodRx by 6.3% in the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock valued at $6,823,000 after purchasing an additional 58,610 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of GoodRx during the 3rd quarter worth about $5,675,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of GoodRx by 12.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 538,588 shares of the company’s stock worth $2,504,000 after buying an additional 58,465 shares in the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Performance

Shares of NASDAQ:GDRX opened at $4.64 on Friday. The business has a 50-day moving average of $4.73 and a two-hundred day moving average of $5.68. The firm has a market capitalization of $1.77 billion, a PE ratio of -154.67, a P/E/G ratio of 2.46 and a beta of 1.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GDRX shares. Morgan Stanley reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Mizuho initiated coverage on GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target on the stock. Wells Fargo & Company lowered their price objective on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Barclays dropped their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Finally, KeyCorp decreased their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.